We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Read MoreHide Full Article
Key Takeaways
Xenon reported a Q3 loss of $1.15 per share, narrower than the Zacks Consensus Estimate of a $1.16 loss.
Higher R&D costs reflected progress in late-stage azetukalner studies for epilepsy and mood disorders.
XENE's $555.3M cash reserve as of September end is expected to fund operations and key studies into 2027.
Xenon Pharmaceuticals (XENE - Free Report) reported a loss of $1.15 per share for the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.16. The company had incurred a loss of 81 cents per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX - Free Report) . The company did not recognize any revenues in the year-ago quarter as well.
XENE's Q3 Results in Detail
In the third quarter, research and development (R&D) expenses increased 35% year over year to $77.1 million. The uptick was primarily due to increased expenses related to the company’s ongoing azetukalner late-stage studies in epilepsy and major depressive disorder (MDD), start-up costs for the azetukalner phase III bipolar depression (BPD) program, and higher personnel expenses from a larger workforce.
General and administrative expenses totaled $19.3 million in the reported quarter, up 16% year over year due to an increase in professional and consulting fees.
Xenon had cash, cash equivalents and marketable securities worth $555.3 million as of Sept. 30, 2025, compared with $624.8 million as of June 30, 2025. The company expects its existing cash balance to fund its current operating plans, which include the completion of the azetukalner phase III epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD into 2027.
Year to date, XENE shares have gained 4.9% compared with the industry’s 12% growth.
Image Source: Zacks Investment Research
XENE's Pipeline Updates
Xenon’s lead pipeline candidate, azetukalner, is in late-stage studies for treating focal onset seizures (FOS). Under the phase III epilepsy program, two identical phase III studies, X-TOLE2 and X-TOLE3, are evaluating 15 mg or 25 mg doses of azetukalner, administered with food as adjunctive treatment in patients with FOS. The first top-line data readout from the X-TOLE2 study, which recently completed patient enrollment, is anticipated in early 2026. The X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions.
XENE is also evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study, which is currently enrolling patients.
Xenon’s first two of three planned phase III clinical studies, X-NOVA2 and X-NOVA3, evaluating azetukalner in patients with MDD, are currently underway.
XENE’s first of two phase III clinical studies, X-CEED, to evaluate azetukalner in patients with BPD I and BPD II, is also currently ongoing.
Xenon has initiated two separate early-stage studies evaluating XEN1120 and XEN1701, targeting Kv7 and Nav1.7, respectively, for a range of therapeutic indications, including seizure disorders, pain, and neuropsychiatric disorders, such as MDD and BPD.
XENE, in collaboration with Neurocrine Biosciences, is currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, in a phase I study as a potential treatment for certain types of epilepsy. Earlier this year, Xenon received a $7.5 million milestone payment from Neurocrine Biosciences in connection with the progress of NBI-921355 into a clinical-stage study.
Xenon Pharmaceuticals Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.36 to $4.23 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.41 to $4.21. Year to date, shares of BEAM have lost 2.2%.
Beam Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 2.62%.
In the past 60 days, estimates for Amicus Therapeutics’ earnings per share have remained constant at 31 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 69 cents to 70 cents. Year to date, shares of FOLD have lost 5.9%.
Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark thrice, with the average negative surprise being 24.38%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Key Takeaways
Xenon Pharmaceuticals (XENE - Free Report) reported a loss of $1.15 per share for the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.16. The company had incurred a loss of 81 cents per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX - Free Report) . The company did not recognize any revenues in the year-ago quarter as well.
XENE's Q3 Results in Detail
In the third quarter, research and development (R&D) expenses increased 35% year over year to $77.1 million. The uptick was primarily due to increased expenses related to the company’s ongoing azetukalner late-stage studies in epilepsy and major depressive disorder (MDD), start-up costs for the azetukalner phase III bipolar depression (BPD) program, and higher personnel expenses from a larger workforce.
General and administrative expenses totaled $19.3 million in the reported quarter, up 16% year over year due to an increase in professional and consulting fees.
Xenon had cash, cash equivalents and marketable securities worth $555.3 million as of Sept. 30, 2025, compared with $624.8 million as of June 30, 2025. The company expects its existing cash balance to fund its current operating plans, which include the completion of the azetukalner phase III epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD into 2027.
Year to date, XENE shares have gained 4.9% compared with the industry’s 12% growth.
Image Source: Zacks Investment Research
XENE's Pipeline Updates
Xenon’s lead pipeline candidate, azetukalner, is in late-stage studies for treating focal onset seizures (FOS). Under the phase III epilepsy program, two identical phase III studies, X-TOLE2 and X-TOLE3, are evaluating 15 mg or 25 mg doses of azetukalner, administered with food as adjunctive treatment in patients with FOS. The first top-line data readout from the X-TOLE2 study, which recently completed patient enrollment, is anticipated in early 2026. The X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions.
XENE is also evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study, which is currently enrolling patients.
Xenon’s first two of three planned phase III clinical studies, X-NOVA2 and X-NOVA3, evaluating azetukalner in patients with MDD, are currently underway.
XENE’s first of two phase III clinical studies, X-CEED, to evaluate azetukalner in patients with BPD I and BPD II, is also currently ongoing.
Xenon has initiated two separate early-stage studies evaluating XEN1120 and XEN1701, targeting Kv7 and Nav1.7, respectively, for a range of therapeutic indications, including seizure disorders, pain, and neuropsychiatric disorders, such as MDD and BPD.
XENE, in collaboration with Neurocrine Biosciences, is currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, in a phase I study as a potential treatment for certain types of epilepsy. Earlier this year, Xenon received a $7.5 million milestone payment from Neurocrine Biosciences in connection with the progress of NBI-921355 into a clinical-stage study.
Xenon Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Xenon Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Xenon Pharmaceuticals Inc. Quote
XENE's Zacks Rank & Stocks to Consider
Xenon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Beam Therapeutics (BEAM - Free Report) and Amicus Therapeutics (FOLD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.36 to $4.23 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.41 to $4.21. Year to date, shares of BEAM have lost 2.2%.
Beam Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 2.62%.
In the past 60 days, estimates for Amicus Therapeutics’ earnings per share have remained constant at 31 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 69 cents to 70 cents. Year to date, shares of FOLD have lost 5.9%.
Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark thrice, with the average negative surprise being 24.38%.